# Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck

> **NCT00581360** · PHASE2 · COMPLETED · sponsor: **University of Pittsburgh** · enrollment: 10 (actual)

## Conditions studied

- Adenoid Cystic Carcinoma

## Interventions

- **DRUG:** doxorubicin and bortezomib

## Key facts

- **NCT ID:** NCT00581360
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2016-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00581360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00581360, "Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00581360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*